Pregnancy Outcomes of Women Receiving Compounded 17 α-Hydroxyprogesterone Caproate for Prophylactic Prevention of Preterm Birth 2004 to 2011
02 February 2012
23 February 2012
10 May 2012 (online)
Objective To examine pregnancy outcomes of women receiving weekly compounded 17 α-hydroxyprogesterone caproate (17P) injections through a home nursing program compared with those reported in a multicenter trial by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Network.
Methods The study sample was comprised of patients receiving compounded 17P through a home nurse administration care management program. Included were women with current singleton gestation and prior spontaneous preterm birth (SPTB) initiating 17P between 16 and 20 weeks. Maternal characteristics and pregnancy outcomes were compared between study group and NICHD Network trial patients.
Results Women (n = 5493) received a mean of 16.9 ± 4.0 injections. Of the 92,700 injections, 98.4% were administered within the recommended 5- to 9-day interval. Recurrent SPTB occurred in 28.3%. The overall rate of SPTB at <37 weeks was similar for black and nonblack women (p = 0.592). Within black or nonblack groups, preterm birth rates at <37 weeks were similar regardless of gestational age at start of 17P (p = 0.894 and p = 0.374, respectively). These results were similar to those reported in the multicenter trial. Fetal and neonatal death occurred in 0.8% (46/5493). No significant difference was observed in rate of fetal or neonatal death by gestational age at initiation of 17P (p = 0.478).
Conclusion Home nurse administration of compounded 17P is safe and effective.
- 1 Meis PJ, Klebanoff M, Thom E , et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348: 2379-2385
- 2 American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Use of progesterone to reduce preterm birth. Obstet Gynecol 2003; 102 (5 Pt 1) 1115-1116
- 3 Society for Maternal Fetal Medicine Publications Committee. ACOG Committee Opinion number 419 October 2008 (replaces No. 291, November 2003). Use of progesterone to reduce preterm birth. Obstet Gynecol 2008; 112: 963-965
- 4 Ness A, Dias T, Damus K, Burd I, Berghella V. Impact of the recent randomized trials on the use of progesterone to prevent preterm birth: a 2005 follow-up survey. Am J Obstet Gynecol 2006; 195: 1174-1179
- 5 US Food and Drug Administration. Safety: heparin sodium injection. June 2010. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm219000.htm . Accessed February 28, 2011
- 6 Gershanik J, Boecler B, Ensley H, McCloskey S, George W. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med 1982; 307: 1384-1388
- 7 CDC MMWR Weekly. Neonatal deaths associated with use of benzyl alcohol—United States. June 11, 1982;31:290–291. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm . Accessed December 12, 2011
- 8 Food and Drug Administration, Center for Drug Evaluation and Research. Statistical review and evaluation, Clinical studies; NDA 21–945. Reference ID: 2900768. Available at: www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm252978.pdf . Accessed January 9, 2012
- 9 Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting. Am J Obstet Gynecol 2007; 197: 262 , e1–e4
- 10 Rebarber A, Fox NS, Klauser CK , et al. Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice. J Matern Fetal Neonatal Med 2010; 23: 1139-1142
- 11 González-Quintero VH, Istwan NB, Rhea DJ, Smarkusky L, Hoffman MC, Stanziano GJ. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery. J Matern Fetal Neonatal Med 2007; 20: 249-252
- 12 How HY, Barton JR, Istwan NB, Rhea DJ, Stanziano GJ. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?. Am J Obstet Gynecol 2007; 197: 260 , e1–e4
- 13 Rebarber A, Ferrara LA, Hanley ML , et al. Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007; 196: 224 , e1–e4
- 14 Rebarber A, Cleary-Goldman J, Istwan NB , et al. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage. Am J Perinatol 2008; 25: 271-275
- 15 Ventolini G, Duke J, Po W , et al. The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate. J Reprod Med 2008; 53: 667-671
- 16 Joy S, Rhea DJ, Istwan NB, Desch CN, Stanziano G. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention. Am J Perinatol 2010; 27: 343-348
- 17 Gonzalez-Quintero VH, Cordova YC, Istwan NB , et al. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery. Am J Obstet Gynecol 2011; 205: 275 , e1–e5
- 18 González-Quintero VH, de la Torre L, Rhea DJ , et al. Impact of prior gestational age at preterm delivery on effectiveness of 17-alpha-hydroxyprogesterone caproate in practice. Am J Obstet Gynecol 2010; 203: 257 , e1–e5
- 19 Barton JR, Barton LA, Istwan NB, Rhea DJ, Desch CN, Sibai BM. 17-alphahydroxyprogesterone caproate in women with previous spontaneous preterm delivery: does a previous term delivery affect the rate of recurrence?. Am J Obstet Gynecol 2011; 205: 269 , e1–e6
- 20 Coleman S, Wallace L, Alexander J, Istwan N. Recurrent preterm birth in women treated with 17 alpha-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy. J Matern Fetal Neonatal Med 2011; ; October 12 (Epub ahead of print)
- 21 Rebarber A, Istwan NB, Russo-Stieglitz K , et al. Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care 2007; 30: 2277-2280
- 22 O'Brien JM, Ho SJ, Istwan NB, Stanziano GJ, Rhea DJ, Barton JR. Uterine activity in women receiving 17 alpha-hydroxyprogesterone caproate for the prevention of preterm birth: an observational study. Am J Perinatol 2010; 27: 157-162
- 23 KV Pharmaceuticals. Independent laboratory testing demonstrates important quality differences between FDA approved Makena® and compounded 17P formulations. Press release November 8, 2011. Available at: www.kvph.com/news_center_article.aspx . Accessed January 9, 2012
- 24 US Food and Drug Administration. FDA statement on Makena, November 8, 2011. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm279098.htm . Accessed December 12, 2011